Press/Media
- 200 - 225 out of 630 results
Search results
-
HEALTH CARE SECTOR DAILY: ANNOUNCEMENTS AND PRESS RELEASES OF LISTED COMPANIES WEDNESDAY APRIL 06, 2022
6/04/22
1 item of Media coverage
Press/Media
-
Sema4 And Mount Sinai Use Integrative Network Analysis To Identify Potential New Lung Cancer Therapy
5/04/22
13 items of Media coverage
Press/Media
-
Immunotherapy Before Liver Cancer Surgery Can Kill Tumor, and Likely Residual Cancer Cells
Thomas Marron & Miriam Merad
19/01/22 → 3/04/22
11 items of Media coverage
Press/Media
-
US Patent Issued to Icahn School of Medicine at Mount Sinai on March 29 for "Compositions and methods for treating CDK4/6-mediated cancer" (New York, New Jersey Inventors)
XUEWEI WU & Poulikos Poulikakos
30/03/22
1 item of Media coverage
Press/Media
-
New Method to Identify Early-stage Lung Cancers Identified
26/03/22
1 item of Media coverage
Press/Media
-
Mount Sinai Researchers Develop Novel Method to Identify and Treat Aggressive Early-Stage Lung Cancers
24/03/22 → 26/03/22
5 items of Media coverage
Press/Media
-
-
Researchers develop novel method to identify and treat aggressive early-stage lung cancers
24/03/22 → 25/03/22
2 items of Media coverage
Press/Media
-
Novel method to identify and treat aggressive early-stage lung cancers
24/03/22
1 item of Media coverage
Press/Media
-
FDA approves Janssen's Carvykti for multiple myeloma.(RX Retail Pharmacy: BRANDED DRUGS)
14/03/22
1 item of Media coverage
Press/Media
-
Carvykti Approved for Relapsed/Refractory Multiple Myeloma
2/03/22
1 item of Media coverage
Press/Media
-
US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma
2/03/22
1 item of Media coverage
Press/Media
-
-
Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma
1/03/22
1 item of Media coverage
Press/Media
-
FDA Approves Carvykti for Relapsed or Refractory Multiple Myeloma
1/03/22
2 items of Media coverage
Press/Media
-
Janssen's First Cell Therapy Approved by FDA for Patients with Multiple Myeloma
1/03/22
2 items of Media coverage
Press/Media
-
U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
28/02/22 → 1/03/22
37 items of Media coverage
Press/Media
-
FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma
1/03/22
1 item of Media coverage
Press/Media
-
Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End Points
26/02/22
1 item of Media coverage
Press/Media
-
Pre-Op Treatment May Be Advance Against Deadly Liver Cancers
28/01/22 → 3/02/22
170 items of Media coverage
Press/Media